
FDA approves venglustat, the first oral therapy for Type 3 Gaucher neurological symptoms.
Stephen Tindal, Director Softgel Formulation at Catalent, talks with Pharm Tech about manufacturing issues with soft gels.
Stephen Tindal, Director Softgel Formulation at Catalent, discusses softgel manufacturing issues with Science Editor Adeline Siew.